Home › Funds › Soleus Capital Management, L.P. › KRYS

Soleus Capital Management, L.P. position in KRYS

KRYSTAL BIOTECH INC · Health Care

Soleus Capital Management, L.P. reported holding 939,254 shares of KRYS (KRYSTAL BIOTECH INC) in its Q2 2026 13F filing — a position valued at US$349.1M, representing 12.03% of its reported portfolio and ranking #1 among its reported holdings. Soleus Capital Management, L.P. has disclosed KRYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)939.25K sh
Reported value held$349.09M
Portfolio Weight12.03%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s KRYS position evolved

Soleus Capital Management, L.P. first disclosed a stake in KRYS in Q3 2023 at 117,892 shares (US$13.7M). The position peaked in Q2 2026 at 939,254 shares, worth US$349.1M. Across 12 filings, Soleus Capital Management, L.P. increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 939,254 shares valued at US$349.1M — a reduction of -213,833 shares quarter over quarter.. Notable position changes include a 110% increase in Q1 2024 (shares rose 3% over the following quarter), a 72% increase in Q3 2024 (shares fell 14% over the following quarter), a 109% increase in Q2 2025 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 117.89K $13.68M New
Q4 2023 40.00K $4.96M Reduce
Q1 2024 84.10K $14.96M Add
Q2 2024 126.00K $23.14M Add
Q3 2024 216.98K $39.50M Add
Q4 2024 358.38K $56.14M Add
Q1 2025 441.76K $79.65M Add
Q2 2025 922.96K $126.87M Add
Q3 2025 1.02M $179.85M Add
Q4 2025 941.06K $232.01M Reduce
Q1 2026 1.15M $297.87M Add
Q2 2026 939.25K $349.09M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KRYS and 13F data

KRYS (KRYSTAL BIOTECH INC) is a Health Care company. 48 other funds we track also report a position in KRYS — the largest reported positions include Avoro Capital Advisors LLC (US$1.07B), Hood River Capital Management LLC (US$246.6M), Redmile Group, LLC (US$234.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KRYS

All KRYS fund holders →

FAQ

How long has Soleus Capital Management, L.P. held KRYS?

Soleus Capital Management, L.P. has disclosed KRYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in KRYS?

As of Q2 2026, Soleus Capital Management, L.P. holds 939.25K shares of KRYS (KRYSTAL BIOTECH INC), valued at $349.09M, representing 12.03% of its reported portfolio and ranking #1.

Has Soleus Capital Management, L.P. been buying or selling KRYS?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in KRYS. The position peaked in Q2 2026 at 939.25K shares.

Which other funds hold KRYS?

Other major institutional holders of KRYS include Avoro Capital Advisors LLC, Hood River Capital Management LLC, Redmile Group, LLC, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.